Media & PR
Binger Strasse 173
55216 Ingelheim am Rhein
• Total investment: over 40 million euros
• Planned workforce expansion to 80 employees by 2016
• Animal Health revenue in 2011: around one billion euros worldwide
Ingelheim/Hanover, Germany, 27 September 2012 – Today, Boehringer Ingelheim opened its European Research Center for animal vaccines in Hanover and therefore its fourth site in Germany. The research-driven pharmaceutical company has invested more than 40 million euros in the “Boehringer Ingelheim Veterinary Research Center” (BIVRC). At the moment, 50 employees are already working on developing innovative vaccines for livestock. By 2016, a total of 80 highly qualified scientists, laboratory workers and animal keepers are expected to work at the BIVRC.
“The Animal Health business is of fundamental strategic importance for us and contributed with around one billion euros significantly to the company's total net sales in 2011", explained Hubertus von Baumbach, who is responsible for Finance and Animal Health on Boehringer Ingelheim’s Board of Managing Directors. With the new site in Hanover, the company has set another strategically important milestone by establishing the research and development of animal vaccines in Europe.
“We are glad that with Boehringer Ingelheim, an internationally renowned pharmaceutical company is establishing itself in Lower Saxony, which strengthens our research sector and enriches the region as an attractive employer”, commented Jörg Bode, Minister for Economic Affairs, Labour and Transport of Lower Saxony, Germany.
Vaccines are used to prevent diseases, resulting in fewer antibiotics being needed to treat animals. This is active consumer protection as a reduced treatment of livestock with antibiotics decreases the risk of developing resistance and leads to an improved quality of food of animal origin. “Prevention is better than treatment. With our focus on research and development of vaccines, we promote sustainable methods to maintain the animals’ health“, stressed Dr Randolph Seidler, Head of Global Research and Development in Animal Health at Boehringer Ingelheim.
In Hanover, Boehringer Ingelheim has built a state-of-the-art research center, encompassing over 50 laboratories with animal accommodation facilities. With this facility, the family owned company is considerably expanding its international research and development activities in the area of animal vaccines for livestock. Globally, the company researches and develops animal health medication at sites in the USA, Germany, Mexico, China and Japan. For this purpose, Boehringer Ingelheim continually invests more than 10 % of its revenue from the Animal Health division in research and development.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.
In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.